article · Frontiers in Immunology
Children living in low- and middle-income settings such as Kenya are exposed to <i>Shigella</i> infection starting from the first year of life and acquire serotype-specific antibodies against multiple serotypes. The data from this study suggest that <i>Shigella</i> vaccination should be targeted to infants, ideally at 6 or at least 9 months of age, to ensure children are protected in the second year of life when exposure significantly increases.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fimmu.2024.1340425
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
